News Column

Studies from University of Copenhagen in the Area of Skin Cancer Described

May 27, 2014

By a News Reporter-Staff News Editor at Cancer Weekly -- Researchers detail new data in Oncology. According to news reporting out of Roskilde, Denmark, by NewsRx editors, research stated, "To explore the application of optical coherence tomography (OCT) imaging of basal cell carcinomas (BCC) and actinic keratosis (AK) before, during and after imiquimod treatment and the ability of OCT to predict treatment outcome. The study subjects were 20 patients with biopsy-verified BCC (9) or AK (11)."

Our news journalists obtained a quote from the research from the University of Copenhagen, "Patients were OCT-scanned before, after 1 and 4weeks of imiquimod treatment and after 3 months. Lesions were identified clinically and with OCT. Thickness and morphology of the lesions were recorded at each visit. Any remaining lesions were biopsied at follow-up. Complete data sets were available for 16 patients (8 women and 8 men aged 52-82years), four in-compliant patients were excluded. OCT identified all lesions. Previously suggested OCT-criteria identified 5/8 BCCs. Crusting, ulceration and active treatment significantly reduced image quality. All BCCs cleared, but at follow-up residual structures were seen clinically in 4 cases. OCT and histology both ruled out residual BCC. For AKs significant thinning occurred after 1week of treatment (P=0.04). Imiquimod cleared 2/8 AKs, and significantly decreased the thickness of all lesions (P=0.02). OCT could identify superficial BCC and AK before treatment. Monitoring during imiquimod treatment revealed impaired image quality most likely caused by inflammation, crusting and ulceration. On follow-up, OCT showed thinning of AKs indicating effect of treatment."

According to the news editors, the research concluded: "All treated BCCs cleared, but where residual tissue was suspected clinically this could be ruled out by OCT."

For more information on this research see: Optical coherence tomography imaging of non-melanoma skin cancer undergoing imiquimod therapy. Skin Research and Technology, 2014;20(2):170-176. Skin Research and Technology can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell -; Skin Research and Technology -

Our news journalists report that additional information may be obtained by contacting C.A. Banzhaf, University of Copenhagen, Roskilde Hosp, Dept. of Dermatol, DK-4000 Roskilde, Denmark. Additional authors for this research include L. Themstrup, H.C. Ring, M. Mogensen and G.B.E. Jemec (see also Oncology).

Keywords for this news article include: Europe, Denmark, Therapy, Roskilde, Oncology, Skin Neoplasms, Imaging Technology, Non-Melanoma Skin Cancer, Non-Melanoma Skin Carcinoma, Optical Coherence Tomography

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Cancer Weekly

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters